Pretre, Vincent, Papadopoulos, Dimitrios, Regard, Jean, Pelletier, Marc and Woo, Janghee (2022) Interleukin-1 (IL-1) and the inflammasome in cancer. Cytokine, 153. ISSN 1043-4666

Abstract

Inflammation is a hallmark of cancer and while exciting preclinical and clinical data has emerged implicating inflammation in the development and progression of certain cancer, our mechanistic understanding of how distinct inflammatory pathways are contributing to specific stages and types of cancer is still at an early stage. Malignancies are known to arise in areas of chronic inflammation and inflammation in the tumor microenvironment (often called tumor-promoting inflammation) is believed to allow cancer cells to evade immunosurveillance while promoting genetic instability, survival and progression. Among the strongest data suggesting a causal role for inflammation in cancer comes from the recent CANTOS trial which demonstrated that chronic IL-1β inhibition with canakinumab leads to a significant, dose-dependent decrease in incident lung cancer. This observation has launched a series of additional clinical studies to understand the role of IL-1β and inflammasome in cancer and when, during the course of disease progression, inhibition of IL-1β provides patients with disease altering benefit. In this article we will review recent data implicating IL-1β signaling and its upstream regulator NLRP3 in both solid tumor and hematologic malignancies. We will discuss the key preclinical observations and the current clinical landscape, and describe the pharmacologic tools which will be used to evaluate the effects of blocking tumor-promoting inflammation clinically.

Item Type:	Article
Date Deposited:	02 Jun 2022 00:45
Last Modified:	02 Jun 2022 00:45
URI:	https://oak.novartis.com/id/eprint/46002